Avidity Biosciences, trading on the NASDAQ under the symbol RNA, is a biotechnology company focused on developing RNA therapies. On October 27, 2025, Boobalan Pachaiyappan from Roth Capital set a price target of $72 for NASDAQ:RNA, while the stock was priced at $49.15. This suggests a potential price increase of about 46.49%.
The recent surge in RNA's stock price, up by 42% in premarket trading, is driven by Novartis's announcement to acquire Avidity Biosciences for $12 billion, offering $72 per share in cash. This acquisition underscores Big Pharma's growing interest in RNA therapies, as highlighted by Seeking Alpha. The deal is Novartis's largest in over a decade, aiming to enhance its portfolio amid rising generic competition.
Despite the acquisition news, Novartis shares fell by 1% on the announcement day, as reported by Reuters. This acquisition is a strategic move by Novartis to secure potential blockbuster treatments, as noted by Sam Fazeli from Bloomberg Intelligence. The deal reflects Novartis's commitment to strengthening its position in the biotech sector.
RNA's stock, currently priced at $49.15, has seen a daily fluctuation between $48.80 and $50.23. Over the past year, the stock has ranged from a low of $21.51 to a high of $56. The company's market capitalization is approximately $6.32 billion, with a trading volume of 1,269,675 shares. This acquisition news has significantly impacted RNA's market performance.
